GlossaryMechanismGIP Receptor
Mechanism

GIP Receptor

Also known as: GIPR · gastric inhibitory polypeptide receptor

The GIP receptor is the receptor for GIP, a gut incretin hormone that boosts insulin after meals; tirzepatide activates it along with the GLP-1 receptor.

GIP (glucose-dependent insulinotropic polypeptide) is a 42-amino-acid hormone released from K cells in the upper small intestine when you eat glucose or fat. It belongs to the secretin family of gut peptides and was first named "gastric inhibitory polypeptide" because it can reduce stomach acid secretion. Like GLP-1, it is an incretin: it amplifies insulin release after a meal. One recent review estimates that GIP accounts for 60% to 80% of the insulin response after eating, which would make it the main incretin in healthy people.

The GIP receptor sits on pancreatic beta cells and on other tissues, including fat. GIP favors storing nutrients, both directly and by raising insulin, and people with obesity tend to secrete more of it. That is why some researchers have argued GIP may worsen insulin resistance, and why its role in obesity treatment is debated.

Why it matters

GIP is the paradox of modern obesity pharmacology. Combining GIP receptor activation with GLP-1 receptor activation has shown benefit in treating obesity, by mechanisms that are not yet fully worked out. Yet blocking GIP signaling, genetically or with antibodies, also reduced obesity in preclinical models, and whether that carries over to people is still unknown. Treat any confident one-line explanation of "what GIP does for fat loss" with caution.

Tirzepatide is the dual GIP and GLP-1 receptor agonist. In the SURPASS-2 trial, 1,879 adults with type 2 diabetes were randomized to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg weekly for 40 weeks. HbA1c fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide versus 1.86 with semaglutide, and weight loss was greater with tirzepatide by 1.9, 3.6 and 5.5 kg. Serious adverse events were reported in 5% to 7% of tirzepatide patients and 3% of semaglutide patients. The trial compared two different molecules at specific doses, so it does not tell you how much of the difference came from the GIP component.

How to read a dual-agonist claim

  1. List which receptors the molecule activates and whether the evidence is from people or animals.
  2. Ask whether the comparison isolates the GIP part; a head-to-head of two different drugs does not.
  3. Note the doses compared and the population (diabetes or not).
  4. Subtract the comparator result to get the difference, then check side effects and discontinuations.

Difference versus comparator = change with drug A - change with drug B

Worked example

SURPASS-2, 15 mg arm: -2.30 - (-1.86) = -0.44 HbA1c percentage points by simple subtraction; the trial's adjusted estimate was -0.45.

Common mistakes

  • Crediting all of tirzepatide's effect to GIP receptor activation; the trials do not separate the two receptors.
  • Assuming GIP receptor activation on its own causes weight loss; the clinical benefit has been shown in combination with GLP-1 agonism.
  • Treating the antibody results in mice and monkeys as proof that GIP blockers work in people.
  • Confusing the old name "gastric inhibitory polypeptide" with a different hormone; it is the same GIP.
  • Assuming a research-market vial labeled tirzepatide matches the product used in trials.

Sources

  1. ReviewGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease. Endocr Rev, 2025. PMID 39951489.
  2. Clinical trialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 2021. PMID 34170647.
  3. Preclinical studyAnti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med, 2018. PMID 30567927.

Page updated . How we grade evidence: methodology.

Related Terms

GLP-1 Receptor

The GLP-1 receptor is the G protein-coupled receptor that GLP-1 activates to boost insulin, lower glucagon, slow the stomach and reduce appetite.

GLP-1 Agonist

A GLP-1 agonist is a drug that activates the receptor for glucagon-like peptide-1 (GLP-1), a gut hormone, and is used to lower blood glucose and body weight.

Receptor Agonist

A receptor agonist is a molecule that binds a receptor and switches it on, producing a response the way the body's own signaling molecule does.

Look up any peptide term inside DoseCraft Pro

The glossary is just the start. Inside DoseCraft you get 90+ compound deep-dives, a PK-aware protocol engine, interaction checker, and vendor trust scores — every term surfaced in protocol-design context, not a separate page.

Start Free Trial